Myelo Therapeutics GmbH

📍 Berlin, Germany🗓 Founded 2013👥 12 employees💰 Last funded Jan 2022
Biotechnology🌐 myelotherapeutics.com
Website LinkedIn
Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs. Its lead compound, myelo001, is a small molecule that is effective on the hematogenesis. Its oral application is being investigated as a treatment for - chemotherapy-induced myelosuppression (CIM), including chemotherapy-induced neutropenia (CIN), chemotherapy-induced thrombocytopenia, and chemotherapy-induced lymphocytopenia - radiation-induced myelosuppression (RIM) - acute radiation syndrome (ARS).
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Myelo Therapeutics GmbH?
Myelo Therapeutics GmbH has 1 investors on record on gritt.io and 1 late-stage investors.
When did Myelo Therapeutics GmbH last raise funding?
The most recent investment in Myelo Therapeutics GmbH recorded on gritt.io was in January 2022.
When was Myelo Therapeutics GmbH founded?
Myelo Therapeutics GmbH was founded in 2013.
What industry is Myelo Therapeutics GmbH in?
Myelo Therapeutics GmbH operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Myelo Therapeutics GmbH based?
Myelo Therapeutics GmbH is headquartered in Berlin, Germany.